Cargando…

Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis

Detalles Bibliográficos
Autores principales:	Zolopa, A, Towner, W, Lazzarin, A, Fätkenheuer, G, Butcher, D, Uy, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112910/ http://dx.doi.org/10.1186/1758-2652-13-S4-P134

Ejemplares similares

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
por: Esker, S, et al.
Publicado: (2010)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

AIS Project Final Report
por: Ferguson, J, et al.
Publicado: (2000)

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

BMS1 Is Mutated in Aplasia Cutis Congenita
por: Marneros, Alexander G.
Publicado: (2013)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load
por: Luz, Ana Júlia, et al.
Publicado: (2013)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir
por: Beckman, Joshua A., et al.
Publicado: (2017)

Role of miRNA-424 in Cancers
por: Li, Shulin, et al.
Publicado: (2020)

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity
por: Feng, Joy Y., et al.
Publicado: (2017)

Effect of BMS-470539 on lipopolysaccharide-induced neutrophil activation
por: Lee, Seongheon, et al.
Publicado: (2020)

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients
por: Ferretti, Francesca, et al.
Publicado: (2016)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano, Roberto, et al.
Publicado: (2013)

Ureteral Obstruction Due to Radiolucent Atazanavir Ureteral Stones
por: Grant, Michael T., et al.
Publicado: (2017)

Atazanavir Crystal–Induced Chronic Granulomatous Interstitial Nephritis
por: Varghese, Vipin, et al.
Publicado: (2020)

Atazanavir/efavirenz/lamivudine: Covid-19: case report
Publicado: (2021)

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations
por: Rhee, Soo-Yon, et al.
Publicado: (2022)

Long-Term Gender-Based Outcomes for Atazanavir/Ritonavir (ATV/r)-Containing Regimens in Treatment-Experienced Patients with HIV
por: Svedhem-Johansson, Veronica, et al.
Publicado: (2013)

Phase I study of the mitomycin C analogue BMS-181174.
por: Macaulay, V. M., et al.
Publicado: (1998)

Identification and Preclinical Pharmacology of the γ-Secretase Modulator BMS-869780
por: Toyn, Jeremy H., et al.
Publicado: (2014)

A Behaviour Monitoring System (BMS) for Ambient Assisted Living
por: Eisa, Samih, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ksacmkesdl1t81g16eb87nj2rh